OmahaCell therapy reversed symptoms in 26 autoimmune patients.
Chimeric antigen receptor T cells target and destroy the rogue B cells driving autoimmune attacks, resetting rather than suppressing immunity.
Hundreds of thousands per dose limits the therapy to clinical trials; off-the-shelf versions could cut cost.
Sources: Ars Technica
THE ORIGINAL TARGET
CAR-T was built for blood cancers. Engineers extract a patient's T cells, splice in a synthetic receptor that recognizes a tumor marker (usually CD19 on B cells), grow billions of copies, and infuse them back. The FDA approved the first version (Kymriah) in 2017 for pediatric leukemia.
WHY B CELLS ARE THE COMMON ENEMY
In lymphoma, B cells are cancerous. In lupus, MS, and myasthenia gravis, B cells produce autoantibodies that attack the patient's own tissue. The same CD19 marker exists on both. A therapy designed to wipe out malignant B cells turns out to wipe out autoimmune ones too.
RESET, NOT SUPPRESS
Standard autoimmune drugs (steroids, biologics like rituximab) suppress the immune system continuously — patients dose for life and accept infection risk. CAR-T depletes B cells down to zero in weeks; the bone marrow then regenerates a fresh B cell repertoire that, for reasons not fully understood, often comes back without the autoimmune programming.
THE COST WALL
A single CAR-T dose lists at $400,000–$500,000 in the US, before hospitalization. The cost is structural: each dose is manufactured bespoke from the patient's own cells in a 2–3 week process. Allogeneic ('off-the-shelf') versions use donor cells engineered to evade rejection — same therapy, factory-scale economics.
CYTOKINE RELEASE SYNDROME
When billions of engineered T cells activate at once, they flood the bloodstream with inflammatory signals. Fever, hypotension, and organ stress follow. CRS is manageable in oncology wards but is the main reason CAR-T has stayed inside hospitals — and the main hurdle for treating autoimmune patients who are otherwise ambulatory.